Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco

被引:11
|
作者
Haban, Houda [1 ,2 ]
Benchekroun, Soumia [3 ]
Sadeq, Mina [4 ]
Benjouad, Abdelaziz [5 ]
Amzazi, Said [2 ]
Oumzil, Hicham [1 ]
Elharti, Elmir [1 ]
机构
[1] Natl Inst Hyg, Dept Virol, Natl Reference Lab HIV, Rabat, Morocco
[2] Univ Mohammed Vth, Immunol Biochem Lab, Fac Sci, Rabat, Morocco
[3] Ibn Sina Univ Hosp, Pediat Infect Dis Clin, Rabat, Morocco
[4] Natl Inst Hyg, Environm Epidemiol Unit, Rabat, Morocco
[5] Int Univ Rabat, Sale, Morocco
来源
BMC PUBLIC HEALTH | 2017年 / 17卷
关键词
HBV vaccine; HIV-infected children; Seroprotection; Morocco; HEPATITIS-B VACCINATION; ACTIVE ANTIRETROVIRAL THERAPY; HIV-1-INFECTED CHILDREN; VIRUS; EFFICACY; IMMUNOGENICITY;
D O I
10.1186/s12889-017-4776-8
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Since its development in the early 1980s, Hepatitis B virus (HBV) vaccine has been proven to be highly protective. However, its immunogenicity may be ineffective among HIV-infected children. In Morocco, HBV vaccine was introduced in 1999, and since then all infants, including vertically HIV-infected infants, have been following the vaccination schedule, implemented by the Moroccan ministry of health. An assessment of the immunization of these children is important to optimize efforts aimed at tackling Hepatitis B coinfection, within the country. Methods: Forty-nine HIV-infected children (HIV group) and 112 HIV uninfected children (control group) were enrolled in this study. Samples were tested by Elisa (Monolisa Anti-HBs, Biorad) to quantify the anti-HBs antibodies. The % of lymphocyte subsets i.e. CD4+ T cells, CD8+ T cells, B cells, and NK, was determined by flow cytometry, using CellQuest Pro software (Becton-Dickinson), and for HIV group, HIV viral load was measured by real time PCR assay (Abbott). All variables were statistically compared in the two groups. Results: The median age was 51 +/- 35 months for the HIV group and 50 +/- 36 months (p > 0.05) for the control group. Female represented 63% and 41% (p = 0.01), among the HIV group and the control group, respectively. Among HIV-infected children, 71.4% (35/49) were under HAART therapy at the enrollment in the study. Seroprotection titer i.e. anti-HBs >= 10 mUI/ml among control group was 76% (85/112), and only 29% (14/49) among the perinatally HIV-infected children (p < 0.0001). Lower % of CD4 + T cells was observed in HIV-infected children with a poor anti-HBs response. Conclusion: In this studied group, we have shown that despite the vaccination of HIV-children with HBV vaccine, 71% did not show any seroprotective response. These findings support the need for monitoring HBV vaccine response among HIV-infected children in Morocco, in order to revaccinate non-immunized children.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Immunogenicity and tolerability of a trivalent virosomal influenza vaccine in a cohort of HIV-infected children
    Zuccotti, GV
    Zenga, A
    Durando, P
    Massone, L
    Bruzzone, B
    Salai, D
    Riva, E
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2004, 32 (05) : 492 - 499
  • [42] HIV drug resistance in HIV-infected children
    Easterbrook, Philippa
    JORNAL DE PEDIATRIA, 2009, 85 (02) : 94 - 96
  • [43] Pneumococcal conjugate vaccine for HIV-infected adults
    Naus, Monika
    BRITISH COLUMBIA MEDICAL JOURNAL, 2015, 57 (02): : 62 - 62
  • [44] Subnormal and waning immunity to tetanus toxoid in previously vaccinated HIV-infected children and response to booster doses of the vaccine
    Choudhury, Shahana A.
    Matin, Fazle
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2013, 17 (12) : E1249 - E1251
  • [45] Heterogeneity and Hierarchy of Immune Response to Primary Immunization in HIV-Infected Children on HAART and the Impact of an Additional Dose of Vaccine
    Mathew, Sonia
    Alex, Diviya
    Demosthenes, John Paul
    Rose, Winsley
    Chacko, Anila
    Kompithra, Rajeev Zachariah
    Ramalingam, Veena Vadhini
    Prakash, John Antony Jude
    Mathai, John
    Fletcher, Gnanadurai John
    Abraham, Priya
    Verghese, Valsan Philip
    Kannangai, Rajesh
    INDIAN JOURNAL OF PEDIATRICS, 2025, 92 (02): : 181 - 184
  • [46] Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda
    Seremba, E.
    Ocama, P.
    Ssekitoleko, R.
    Mayanja-Kizza, H.
    Adams, S., V
    Orem, J.
    Katabira, E.
    Reynolds, S. J.
    Nabatanzi, R.
    Casper, C.
    Phipps, W.
    VACCINE, 2021, 39 (08) : 1265 - 1271
  • [47] Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore
    Lau, Yuk-Fai
    Tang, Lay-Hoon
    Lye, David Chien
    Ooi, Eng-Eong
    Leo, Yee-Sin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (03) : 551 - 560
  • [48] IMPAIRED RESPONSE TO RECOMBINANT HEPATITIS-B VACCINE IN HIV-INFECTED PERSONS
    BRUGUERA, M
    CREMADES, M
    SALINAS, R
    COSTA, J
    GRAU, M
    SANS, J
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 1992, 14 (01) : 27 - 30
  • [49] Antibody Response to a Standard Dose of Hepatitis B Vaccine in HIV-Infected Patients
    Inci, Ayse
    Fincanci, Muzaffer
    KLIMIK JOURNAL, 2014, 27 (01) : 12 - 14
  • [50] Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort
    Thio, Chloe L.
    Smeaton, Laura
    Saulynas, Melissa
    Hwang, Hyon
    Saravan, Shanmugam
    Kulkarni, Smita
    Hakim, James
    Nyirenda, Mulinda
    Iqbal, Hussain S.
    Lalloo, Umesh G.
    Mehta, Anand S.
    Hollabaugh, Kimberly
    Campbell, Thomas B.
    Lockman, Shahin
    Currier, Judith S.
    AIDS, 2013, 27 (02) : 191 - 201